Noxopharm Limited (NOXOF) Research

Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types. LuPIN investigates a combined therapy of Veyonda with 177Lu-PSMA-617 for managing late-stage prostate cancer. The IONIC program explores Veyonda in combination with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, for various solid tumor indications. Its Chemotherapy Enhancement Program (CEP) utilizes Veyonda alongside carboplatin to treat refractory solid tumors found in the breast, head and neck, lung, prostate, and ovaries. Beyond oncology, Noxopharm is advancing the NOXCOVID Program, a dose escalation and expansion study of NOX66, aimed at treating COVID-19 infections. Additionally, the company is pursuing early-stage programs for pancreatic cancer and glioblastoma. Noxopharm Limited has established a collaboration with the Hudson Institute of Medical Research and The Australian National University to conduct research and development into therapeutic drugs for inflammatory disorders. Founded in 2015, the company is based in Chatswood, Australia.

Open Noxopharm Limited (NOXOF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.